Sivapalan, Pradeesh http://orcid.org/0000-0002-8620-3655
Jørgensen, Niklas R.
Mathioudakis, Alexander G.
Eklöf, Josefin
Lapperre, Therese
Ulrik, Charlotte Suppli
Andreassen, Helle F.
Armbruster, Karin
Sivapalan, Praleene
Janner, Julie
Godtfredsen, Nina
Weinreich, Ulla M.
Nielsen, Thyge L.
Seersholm, Niels
Wilcke, Torgny
Schuetz, Philipp
Klausen, Tobias W.
Marså, Kristoffer
Vestbo, Jørgen
Jensen, Jens-Ulrik
Funding for this research was provided by:
Danish Regions Medical Fund (5894/16)
Sundhed og Sygdom, Det Frie Forskningsråd (6110-00268B)
Herlev Hospital
Article History
Received: 26 July 2020
Accepted: 4 October 2020
First Online: 12 October 2020
Ethics approval and consent to participate
: This study was approved by the Ethics Committees of all participating sites (H-15012207), the Danish Medicines Agency (EudraCT no 2015–003441-26) and the Danish Data Protection Agency (HGH-2015-038 and I-Suite number 04014). It was monitored according to Good Clinical Practice (GCP) by the GCP unit of the Capital Region of Denmark. Written informed consent was obtained from patients before randomisation.
: Not applicable.
: None of the authors had conflicts of interest that were directly related to this work. Dr. Sivapalan reports personal fees from Boehringer Ingelheim outside the submitted work. Dr. Mathioudakis reports grants from Boehringer Ingelheim outside the submitted work. Dr. Armbruster reports other from Advisory board BMS PleurX-IPC, outside the submitted work. Dr. Marsaa reports personal fees from GlaxoSmithKline, personal fees from AstaZeneca, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Roche, personal fees from Bristol-Myers Squibb personal fees from Chiesi Pharma, personal fees from Kyowa Kirin AB, personal fees from Norgine, outside the submitted work. Dr. Vestbo reports personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GSK, personal fees from Novartis, outside the submitted work.